F	FORM 4	
	Check this box if no	

Check this box if no					
longer subject to					
Section 16. Form 4 or					
Form 5 obligations may					
continue. See					
Instruction 1(b).					

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

^{may} Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Print of Type Responses)													
1. Name and Address of F Pfost Dale R	2. Issuer Name and eXegenics Inc [EX		radin	g Symbol		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner							
(Last) EXEGENICS INC., 4 SUITE 900	OTT DTT DD	3. Date of Earliest Transaction (Month/Day/Year) 03/29/2007						X Officer (give title below) Other (specify below) President					
(Street) MIAMI, FL 33137			4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(State)	(Zip)	Table I - Non-Derivative Securities Acqu						ired, Disposed of, or Beneficially Owned				
(Instr. 3) D		2. Transaction Date (Month/Day/Year)	Execution Date, if any	(Instr. 8)	4. Securities Acquired (or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	Ownership of Indire	7. Nature of Indirect Beneficial			
			(Month/Day/Year)	Code	v	Amount	(A) or (D)	Price	(Instr. 3 and 4)	Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)		
Common Stock, par va	alue \$.01 per share	03/29/2007		<u>ј(1)</u>		1,687,261	А	\$ 0	1,687,261	D (2)			
Reminder: Report on a sep	parate line for each cla	ss of securities ber	neficially owned dired	-		ons who re	spond	to the	collection of information contained	d in SEC	1474 (9-02)		

this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(<i>e.g.</i> , puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code	tion	5. Number of	of (D) or	6. Date Exercisable and 7. Expiration Date U		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			9. Number of Derivative Securities Beneficially Owned Following Reported	Form of Derivative Security: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)	(I) (Instr. 4)	
Series C Convertible Preferred Stock	\$ 0	03/29/2007		յ <u>(1)</u>		5,189		<u>(3)</u>	<u>(3)</u>	Common Stock	518,900	\$ 0	5,189	D	
Warrant (Right to Buy)	\$ 0.002	03/29/2007		յ <u>(1)</u>		64,868		<u>(4)</u>	03/27/2017	Common Stock	64,868	\$ 0	64,868	D	
Warrant (Right to Buy)	\$ 0.6728	03/29/2007		յ <u>(1)</u>		68,852		<u>(4)</u>	03/27/2017	Common Stock	68,852	\$ 0	68,852	D	
Warrant (Right to Buy)	\$ 0.8473	03/29/2007		յ <u>(1)</u>		68,852		<u>(4)</u>	03/27/2017	Common Stock	68,852	\$ 0	68,852	D	
Warrant (Right to Buy)	\$ 1.0466	03/29/2007		յ <u>(1)</u>		68,852		<u>(4)</u>	03/27/2017	Common Stock	68,852	\$ 0	68,852	D	
Stock Option (Right to Buy)	\$ 31.8	03/29/2007		յ <u>(1)</u>		7,317		<u>(5)</u>	09/24/2014	Series C Convertible Preferred Stock	7,317	\$ 0	7,317	D	
Stock Option (Right to Buy)	\$ 0.04	03/29/2007		յ <u>(1)</u>		430,722		<u>(6)</u>	12/11/2013	Common Stock	430,722	\$ 0	430,722	D	
Stock Option (Right to Buy)	\$ 0.04	03/29/2007		յ <u>(1)</u>		225,740		<u>(5)</u>	09/24/2014	Common Stock	225,740	\$ 0	225,740	D	
Stock Option (Right to Buy)	\$ 0.04	03/29/2007		յ <u>(1)</u>		1,297,357		(7)	02/15/2015	Common Stock	1,297,357	\$ 0	1,297,357	D	
Stock Option (Right to Buy)	\$ 0.05	03/29/2007		յ <u>(1)</u>		311,365		<u>(8)</u>	11/01/2015	Common Stock	311,365	\$ 0	311,365	D	
Stock Option (Right to	\$ 0.05	03/29/2007		յ <u>(1)</u>		311,365		<u>(9)</u>	01/01/2016	Common Stock	311,365	\$ 0	311,365	D	

Reporting Owners

Buy)

Describer Original Manager (Addition	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
Pfost Dale R EXEGENICS INC. 4400 BISCAYNE BOULEVARD, SUITE 900 MIAMI, FL 33137			President					

Signatures

/s/ Dale R. Pfost	03/30/2007
Signature of Reporting Person	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) All securities described were acquired in a merger transaction between Acuity Pharmaceuticals Inc. and eXegenics Inc.

(2) 1,081,116 of these shares are owned jointly by Mr. Pfost and his wife.

(3) These shares are currently exercisable and do not expire.

(4) These warrants are currently exercisable.

(5) These options are fully vested.

(6) 349,657 of these options are fully vested. The balance will vest monthly until fully vested in December 2007.

(7) 675,705 of these options are fully vested. The balance will vest monthly until fully vested in February 2009..

(8) 103,785 of these options are fully vested. The balance will vest monthly until fully vested in November 2009.

(9) 90,814 of these options are fully vested. The balance will vest monthly until fully vested in January 2010.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.